immunolog
mediat
detriment
effect
lung
function
cohort
patient
enrol
patient
clinic
diagnos
viral
rti
asymptomat
patient
nasopharyng
throat
swab
taken
respiratori
viru
antigen
detect
cultur
rtpcr
patient
pulmonari
function
test
regular
interv
month
rate
reject
declin
forc
expiratori
volum
l
bacteri
fungal
superinfect
compar
primari
endpoint
patient
rti
microbi
etiolog
identifi
includ
rhinoviru
coronaviru
rsv
influenza
parainfluenza
human
metapneumoviru
primari
endpoint
rti
patient
acut
reject
versu
nonrti
patient
p
number
patient
experienc
declin
month
rti
versu
nonrti
p
six
nine
patient
declin
sustain
period
consist
bronchiol
obliteran
syndrom
bo
communityacquir
respiratori
virus
may
associ
develop
acut
reject
bo
communityacquir
viral
respiratori
tract
infect
rti
common
caus
acut
respiratori
ill
gener
commun
increasingli
recogn
common
pathogen
solid
organ
transplant
patient
popul
infect
pathogen
occasion
result
sever
pulmonari
diseas
signific
morbid
mortal
common
commun
respiratori
virus
includ
influenza
b
parainfluenza
serotyp
respiratori
syncyti
viru
rsv
adenoviru
rhinovirus
coronavirus
recent
describ
human
metapneumoviru
lung
transplant
emerg
effect
lifesav
treatment
option
number
diseas
result
endstag
lung
diseas
patient
particular
risk
viral
rti
due
number
factor
includ
potent
immunosuppress
regimen
decreas
cough
reflex
due
denerv
transplant
lung
abnorm
lymphat
drainag
impair
mucociliari
clearanc
direct
exposur
allograft
environ
suggest
lung
transplant
recipi
infect
communityacquir
viral
rti
high
rate
progress
sever
viral
pneumon
addit
direct
sequela
accumul
data
primarili
retrospect
studi
suggest
virus
seriou
indirect
effect
specif
may
trigger
immunolog
mediat
lung
injuri
result
develop
acut
chronic
reject
chronic
reject
occur
patient
year
lung
transplant
major
factor
limit
longterm
success
intervent
chronic
reject
defin
oblit
bronchiol
ob
histopatholog
diagnos
clinic
base
sustain
declin
lung
function
bronchiol
obliteran
syndrom
bo
propos
mechan
injuri
like
relat
upregul
inflammatori
cytokin
product
initi
viral
replic
direct
cytopath
effect
respiratori
epithelium
limit
prospect
acquir
data
clinic
impact
communityacquir
viral
rti
lung
transplant
recipi
analyz
perform
prospect
cohort
studi
communityacquir
respiratori
viral
infect
patient
popul
prospect
cohort
studi
lung
transplant
recipi
compar
advers
clinic
outcom
patient
communityacquir
viral
rti
without
total
cohort
includ
lung
transplant
recipi
consist
patient
symptom
compat
communityacquir
viral
rti
rti
group
asymptomat
patient
nonrti
group
patient
enrol
outpati
clinic
toronto
gener
hospit
patient
rti
group
identifi
base
symptom
becam
elig
evalu
physician
princip
investig
agre
clinic
diagnosi
viral
rti
symptom
rti
gener
includ
limit
new
onset
rhinorrhea
sore
throat
cough
inclus
criteria
patient
rti
nonrti
group
includ
stabl
clinic
cours
stabl
forc
expiratori
volum
l
measur
monthli
month
prior
enrol
patient
previou
diagnosi
bo
elig
requir
stabl
lung
function
rejectionfre
minimum
month
prior
enrol
fifti
lung
transplant
patient
rti
identifi
year
round
patient
posit
cmv
antigenemia
posit
sputum
cultur
routin
bacteri
pathogen
time
initi
present
exclud
nonrti
group
asymptomat
lung
transplant
patient
identifi
outsid
peak
respiratori
viru
season
match
time
transplant
subject
rti
group
patient
includ
histori
viral
rti
acut
reject
preced
month
studi
approv
institut
research
ethic
board
inform
consent
obtain
patient
patient
follow
year
subject
follow
regular
pulmonari
function
test
baselin
week
although
month
primari
endpoint
studi
patient
routin
addit
pulmonari
function
test
month
postenrol
chest
radiograph
perform
time
enrol
clinic
indic
patient
follow
prospect
develop
advers
clinic
event
outlin
nasopharyng
oropharyng
swab
perform
rti
nonrti
subject
sampl
immedi
test
presenc
adenoviru
influenza
b
rsv
parainfluenza
viral
cultur
direct
fluoresc
antibodi
test
previous
describ
sampl
frozen
c
underw
test
batch
sampl
also
test
center
diseas
control
atlanta
previous
describ
rtpcr
assay
panel
rsv
parainfluenza
influenza
b
human
metapneumoviru
recent
expand
includ
picornaviru
rhinoviru
enteroviru
adenoviru
brief
nucleic
acid
extract
specimen
use
autom
nuclisen
extract
system
biomerieux
durham
nc
onestep
amplif
reaction
perform
extract
nucleic
acid
use
access
rtpcr
system
promega
corp
madison
wi
oligonucleotid
primer
endlabel
fluorescein
amplifi
product
analyz
abi
prism
genet
analyz
use
genescan
softwar
appli
biosystem
foster
citi
ca
posit
specimen
confirm
second
rtpcr
amplifi
dna
picornaviru
posit
specimen
sequenc
distinguish
rhinoviru
enteroviru
sampl
extract
also
test
rtpcr
bactin
housekeep
gene
evalu
qualiti
extract
rna
monitor
presenc
pcr
inhibitor
sampl
neg
virus
test
rtpcr
assay
specif
human
coronavirus
procedur
use
rtpcr
assay
detect
known
human
coronavirus
describ
speci
coronaviru
confirm
sequenc
amplicon
previous
describ
sputum
set
routin
bacteri
fungal
cultur
patient
also
cytomegaloviru
antigenemia
test
upon
enrol
exclud
possibl
cmv
caus
symptom
primari
endpoint
analysi
advers
event
rti
group
versu
nonrti
group
advers
event
includ
clinic
treat
acut
reject
episod
declin
month
postenrol
bacteri
fungal
superinfect
primari
endpoint
chosen
hypothes
advers
clinic
event
occur
soon
viral
infect
ie
within
month
like
associ
infect
also
nonrti
group
like
longer
followup
time
mani
patient
may
develop
viral
infect
well
therebi
potenti
confound
result
follow
definit
use
assess
outcom
acut
reject
acut
reject
diagnos
basi
transbronchi
biopsi
demonstr
characterist
perivascular
lymphocyt
infiltr
use
criteria
defin
intern
societi
heart
lung
transplant
ishlt
patient
acut
reject
includ
analysi
biopsi
show
grade
higher
reject
patient
biopsi
could
perform
clinic
diagnosi
reject
permit
ie
deterior
lung
function
identifi
etiolog
respond
highdos
corticosteroid
therapi
declin
declin
month
chosen
signific
determin
chronic
allograft
dysfunct
irrevers
declin
posttranspl
maximum
use
definit
bo
consid
signific
patient
declin
month
postenrol
evalu
year
see
met
clinic
definit
bo
histopatholog
definit
ob
clinic
diagnosi
bo
made
use
ishlt
algorithm
base
valu
algorithm
bo
defin
sustain
reduct
maximum
baselin
valu
absenc
anoth
etiolog
bo
stage
stage
indic
progress
worsen
condit
maximum
baselin
valu
respect
diagnosi
ob
made
patholog
ground
presenc
fibrou
scar
wall
small
conduct
airway
partial
complet
obliter
lumen
bacteri
fungal
superinfect
bacteri
fungal
superinfect
diagnos
bronchoalveolar
lavag
bal
cultur
demonstr
bacteri
fungal
pathogen
new
infiltr
develop
chest
radiograph
within
followup
period
patient
complet
followup
includ
analysi
primari
analysi
advers
event
outcom
compar
rti
nonrti
group
use
v
fisher
exact
test
continu
variabl
chang
compar
twotail
ttest
normal
distribut
data
mannwhitney
u
test
nonnorm
distribut
data
statist
analysi
done
use
spss
version
spss
inc
chicago
il
one
hundr
lung
transplant
recipi
recruit
rti
nonrti
studi
period
year
baselin
characterist
patient
shown
tabl
keep
inclus
criteria
patient
clinic
stabl
stabl
month
prior
enrol
studi
age
enrol
gender
time
sinc
transplant
underli
diseas
immunosuppress
compar
two
group
tabl
cmv
infect
month
prior
enrol
document
patient
group
patient
asymptomat
viremia
previou
biopsyproven
acut
reject
requir
treatment
month
prior
enrol
occur
two
patient
rti
group
one
patient
nonrti
group
major
patient
bosfre
enrol
studi
rti
group
six
patient
stabl
bo
prior
enrol
versu
five
patient
nonrti
group
p
ns
patient
nonrti
group
develop
symptom
respiratori
viru
infect
follow
period
mean
time
transplant
year
rti
group
within
first
year
posttranspl
rti
group
patient
cyclosporin
patient
tacrolimu
nonrti
group
patient
cyclosporin
tacrolimu
p
calcineurin
inhibitor
level
time
enrol
similar
rti
nonrti
group
cyclosporin
mean
trough
level
vs
respect
p
ns
subject
rti
enrol
mean
day
onset
symptom
mean
number
symptom
per
patient
outlin
figur
coryza
cough
sore
throat
common
present
symptom
respect
microbi
etiolog
identifi
rti
subject
includ
rhinoviru
n
coronaviru
n
five
two
one
rsv
n
influenza
n
parainfluenza
n
human
metapneumoviru
n
tabl
patient
initi
present
upper
rti
symptom
rate
progress
lower
tract
infect
viral
pneumonia
patient
two
influenza
two
parainfluenza
patient
influenza
treat
oseltamivir
patient
lower
tract
infect
reduct
immunosuppress
reduct
prednison
two
patient
reduct
azathioprin
dose
two
patient
upper
respiratori
infect
except
influenza
treat
antivir
reduct
immunosuppress
recent
discov
coronaviru
patient
sampl
sequenc
amplicon
primer
ident
report
sequenc
primari
followup
period
clinic
treat
acut
reject
occur
rti
patient
versu
nonrti
patient
p
tabl
reject
episod
accompani
drop
patient
treat
highdos
methylprednisolon
bolu
therapi
eight
patient
acut
reject
four
biopsyproven
grade
reject
four
diagnos
clinic
ground
either
biopsi
could
safe
perform
due
poor
lung
function
three
patient
sampl
insuffici
interpret
one
patient
rate
biopsyproven
reject
also
significantli
greater
rti
group
p
mean
time
onset
rti
develop
acut
reject
day
rang
day
figur
specif
viral
etiolog
identifi
seven
eight
patient
subsequ
acut
reject
includ
rhinoviru
n
coronaviru
n
rsv
n
influenza
viru
n
number
patient
experienc
declin
month
rti
patient
versu
nonrti
patient
p
nine
patient
four
posit
respiratori
viru
rhinoviru
coronaviru
influenza
one
patient
preenrol
diagnosi
bo
remain
eight
patient
bosfre
prior
enrol
six
nine
patient
declin
sustain
period
consist
bo
biopsi
andor
autopsi
materi
five
six
patient
confirm
diagnosi
ob
year
followup
two
patient
die
due
progress
bo
patient
improv
lung
function
year
remain
baselin
respect
rti
patient
within
first
year
posttranspl
outcom
similar
beyond
first
year
posttranspl
data
shown
advers
clinic
event
uncommon
invas
fungal
pulmonari
infect
primari
followup
period
occur
one
patient
group
one
rti
patient
blastomycosi
one
nonrti
patient
aspergillosi
bacteri
superinfect
pneumonia
occur
two
patient
rti
group
none
nonrti
group
one
patient
haemophilu
influenza
pneumonia
follow
influenza
one
patient
pseudomona
aeruginosa
pneumonia
follow
rhinoviru
infect
prospect
assess
clinic
impact
communityacquir
respiratori
viru
infect
lung
transplant
recipi
infect
direct
indirect
effect
graft
function
data
suggest
viral
infect
trigger
acut
reject
ultim
chronic
allograft
dysfunct
although
patient
recov
primari
infect
rti
patient
significantli
higher
incid
acut
reject
follow
month
compar
nonrti
patient
addit
patient
drop
postinfect
mani
subsequ
patholog
proven
ob
although
associ
respiratori
virus
bo
alway
suspect
literatur
limit
retrospect
data
data
natur
tend
result
case
ascertain
bia
thu
includ
sever
case
viral
rti
specif
associ
pneumonia
exampl
khalifah
et
al
retrospect
review
lung
transplant
recipi
found
respiratori
viral
infect
patient
increas
risk
bo
death
major
patient
lower
tract
respiratori
infect
similarli
episod
viral
rti
found
review
lung
transplant
recipi
four
patient
develop
ob
two
die
lower
tract
infect
similar
data
group
also
suggest
high
rate
sever
lower
tract
infect
detriment
effect
lung
function
trigger
bo
sinc
viral
infect
detect
clinic
set
extens
microbiolog
investig
includ
use
rtpcr
detect
virus
coronavirus
rhinovirus
metapneumoviru
routin
use
major
previou
studi
sever
uniqu
observ
made
studi
true
rate
progress
lung
transplant
recipi
upper
rti
lower
rti
known
although
gener
presum
high
howev
prospect
studi
rel
rti
subject
progress
lower
rti
rate
progress
lower
tract
infect
may
higher
specif
virus
shown
previou
studi
viral
pneumonia
present
patient
influenza
parainfluenza
respiratori
infect
patient
progress
lower
tract
infect
studi
also
either
influenza
parainfluenza
infect
sought
care
defin
etiolog
viral
rti
patient
studi
use
multipl
test
method
includ
rtpcr
broad
array
virus
addit
commonli
recogn
pathogen
lung
transplant
patient
influenza
rsv
parainfluenza
found
number
infect
due
rhinoviru
coronaviru
sar
one
infect
due
metapneumoviru
none
virus
well
describ
lung
transplant
literatur
although
wellrecogn
caus
communityacquir
rti
immunocompet
person
recent
sever
lower
tract
infect
rhinoviru
nonsar
coronaviru
metapneumoviru
suggest
studi
evalu
immunocompromis
patient
includ
lung
transplant
recipi
use
rtpcr
bal
sampl
obtain
acut
respiratori
event
studi
rhinovirus
coronavirus
togeth
account
microbiolog
confirm
viral
infect
infect
rel
mild
selflimit
subset
patient
howev
associ
seriou
indirect
sequela
exampl
eight
patient
reject
four
prior
rhinoviru
infect
one
prior
coronaviru
infect
one
prior
influenza
one
prior
rsv
one
noteworthi
observ
studi
one
patient
infect
recent
describ
human
coronaviru
knowledg
first
publish
report
infect
organ
transplant
recipi
onethird
rti
subject
viral
etiolog
identifi
studi
despit
compat
clinic
symptom
patient
may
shed
viru
concentr
level
detect
assay
altern
patient
may
atyp
bacteri
etiolog
symptom
mycoplasma
pneumonia
chlamydia
pneumonia
known
unknown
virus
includ
test
panel
time
lag
onset
symptom
specimen
collect
may
also
reduc
yield
virus
interestingli
four
patient
asymptomat
group
without
viral
rti
symptom
also
posit
rhinoviru
rtpcr
although
patient
histori
viral
rti
past
month
exclud
studi
may
result
prolong
shed
immunocompromis
patient
studi
number
limit
possibl
bo
link
sever
initi
viral
rti
abl
adequ
assess
sever
reason
durat
shed
peak
concentr
viru
measur
inher
limit
abil
clinic
assess
sever
diseas
upper
vs
lower
tract
infect
invas
vs
simpl
bronchiti
also
undetect
rti
enrol
may
affect
result
although
patient
specif
ask
symptom
repeat
episod
viral
rti
enrol
subclin
rti
may
gone
undetect
number
factor
associ
develop
bo
lung
transplant
recipi
although
studi
conflict
recent
systemat
review
acut
reject
lymphocyt
bronchiolitisbronch
identifi
risk
factor
bo
cmv
infect
may
also
risk
factor
attempt
control
variabl
patient
clinic
well
reject
free
stabl
month
prior
enrol
includ
studi
incid
acut
reject
month
prior
enrol
low
compar
arm
exclud
posit
cmv
antigenemia
time
enrol
followup
period
three
subject
group
develop
posit
cmv
antigenemia
none
experienc
advers
clinic
event
drop
lung
function
sinc
data
support
associ
viral
infect
subsequ
acut
reject
bo
next
question
whether
specif
intervent
patient
time
infect
warrant
except
influenza
viru
neuraminidas
inhibitor
agent
avail
proven
antivir
therapi
respiratori
viral
infect
limit
aerosol
ribavirin
report
benefici
uncontrol
studi
parainfluenza
rsv
infect
therapi
may
benefici
includ
intraven
immunoglobulin
rsv
immunoglobulin
palivizumab
ribavirin
also
use
parainfluenza
viru
infect
although
good
evid
efficaci
lack
pleconaril
activ
rhinoviru
infect
remain
investig
drug
specif
antivir
agent
exist
coronavirus
final
unknown
whether
treatment
acut
infect
specif
antivir
agent
prevent
amelior
indirect
sequela
infect
summari
previous
stabl
lung
transplant
recipi
communityacquir
viral
rti
rel
low
rate
progress
viral
pneumon
common
etiolog
agent
rhinovirus
coronavirus
acut
infect
selflimit
resolv
without
specif
therapi
howev
viral
infect
even
rel
benign
like
trigger
acut
reject
sustain
declin
lung
function
ultim
develop
ob
therefor
seriou
clinic
sequela
respiratori
viral
pathogen
ubiquit
sinc
antivir
therapi
limit
effect
prevent
method
necessari
